OPsumit USers Registry (OPUS)

What is the purpose of this trial?

Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.

Gender: Both

Actelion Clinical Operations, Inc.

Start Date: 06/29/2015

End Date: 10/01/2018

Last Updated: 02/22/2018

Study HIC#: 1503015421REG

Get Involved

For more information about this study, contact:
Percy Adonteng-Boateng
+1 203-737-4877

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Peter S. Marshall

Principal Investigator